MCCP
REGN icon

Mission Creek Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Mission Creek Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,402
Closed -$999K – 221
2024
Q4 		$999K Sell
1,402
-37
-3% -$31.1K 0.22% 109
2024
Q3 		$1.51M Buy
1,439
+28
+2% +$31.2K 0.35% 87
2024
Q2 		$1.48M Buy
1,411
+924
+190% +$896K 0.37% 78
2024
Q1 		$469K Buy
+487
New +$463K 0.12% 166

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mission Creek Capital Partners's REGN Position: Q1 2025 in Review

Mission Creek Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1,402 shares — an estimated $999K sold.

Mission Creek Capital Partners first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $1.51M in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Mission Creek Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Mission Creek Capital Partners sold 1,402 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $999K.
  • Mission Creek Capital Partners first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Mission Creek Capital Partners's Regeneron Pharmaceuticals position peaked at $1.51M in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Mission Creek Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.